The invention, mTOR inhibitors, and to the group in combination with one or more chemotherapeutic agents selected from the consisting of mitotic inhibitors, to a tee notes of the general formula (1) Ria sol Rhodia diazepine compound (wherein, R 1 is an alkyl carbon number of 1 to 4 and, R 2 is a hydrogen atom a halogen atom or a halogen atom or a hydroxyl group in the optionally substituted alkyl having 1 to 4 carbons, R 3 is a halogen atom a halogen atom, an alkyl carbon number of 1-4, the carbon number is 1 -4 alkoxy, or cyano, optionally substituted phenyl -NR 5 - (CH 2) m -R 6 ( wherein, R 5 is alkyl of 1-4 carbon atoms or a hydrogen atom, m is an integer of 0 to 4 , R 6 is a phenyl or flutes dilim) alkyl optionally substituted with a halogen atom or -NR 7 -CO- (CH 2) n -R 8 ( wherein, R 7 is a hydrogen atom or an alkyl carbon number of 1-4, n is and (CH 2)a -CO-NH-R 9 (wherein, a is an integer of 1-4, - and an integer from 0 to 2, R 8 is phenyl or flutes dilim) alkyl optionally substituted with a halogen atom, R 4 is R 9 is an alkyl carbon number of 1-4 a carbon number of 1 to 4 hydroxy alkyl, a 1 to 4 carbon atoms in alkoxy, or C 1-4 alkyl, 1-4 carbon atoms in the alkoxy, amino or hydroxy optionally substituted phenyl group or flutes dilim) or - (CH2) b -COOR 10 (wherein, b is an integer of 1-4, R 10 is alkyl of a carbon number of 1 to 4), Lim), or a pharmaceutically enemy in that a pharmaceutically acceptable amount of acceptable salt or a hydrate or solvate of the compound comprising the step of administering to a patient mammal provides a method of treating triple negative breast cancer.본 발명은, mTOR 억제제 및 유사분열 억제제로 이루어진 군으로부터 선택된 1 이상의 화학요법제와 조합하여, 하기 화학식 (1)의 티에노트리아졸로디아제핀 화합물(식에서, R1은 탄소수가 1-4인 알킬이고, R2는 수소 원자 할로겐 원자 또는 할로겐 원자 또는 히드록실 기로 임의로 치환된 탄소수가 1-4인 알킬이고, R3은 할로겐 원자 할로겐 원자, 탄소수가 1-4인 알킬, 탄소수가 1-4인 알콕시 또는 시아노로 임의로 치환된 페닐 -NR5-(CH2)m-R6(여기서, R5는 수소 원자 또는 탄소수가 1-4인 알킬이고, m은 0-4의 정수이고, R6은 할로겐 원자로 임의로 치환된 페닐 또는 피리딜임) 또는 -NR7-CO-(CH2)n-R8(여기서, R7은 수소 원자 또는
